IMPROVED ALLOGRAFT HEART VALVE PRESERVATION

Information

  • Research Project
  • 6622249
  • ApplicationId
    6622249
  • Core Project Number
    R44HL059731
  • Full Project Number
    5R44HL059731-03
  • Serial Number
    59731
  • FOA Number
  • Sub Project Id
  • Project Start Date
    1/15/1998 - 26 years ago
  • Project End Date
    10/31/2004 - 20 years ago
  • Program Officer Name
    LUNDBERG, MARTHA
  • Budget Start Date
    2/1/2003 - 21 years ago
  • Budget End Date
    10/31/2004 - 20 years ago
  • Fiscal Year
    2003
  • Support Year
    3
  • Suffix
  • Award Notice Date
    -

IMPROVED ALLOGRAFT HEART VALVE PRESERVATION

DESCRIPTION (provided by applicant): Cryopreserved allogeneic human heart valves are presently the preferred aortic and pulmonary heart valve prostheses for pediatric patients, women of child-bearing age and non-drug compliant patients. Unfortunately, these valves often deteriorate in younger pediatric patients. The objective of this proposal is development of cryopreservation methods that cause less interstitial damage than methods currently employed for preservation of human heart valves. In Phase I we demonstrated significant interstitial ice in heart valves during "conventional" cryopreservation. Since Phase I we have developed relatively non-cytotoxic methods for molecular ice control resulting in either modified or elimination of ice during cryopreservation. In this Phase II proposal ice control formulations will be screened using assays of structural deterioration, calcification, ice formation, morphology and cell viability using rat or sheep heart valve-derived tissues. The best formulation will be scaled up from small volume tissues to clinical-sized specimens using sheep heart valves and validated for human heart valves. Molecular ice control methods of heart valve preservation will be compared with conventionally cryopreserved valves in an allogeneic sheep model. It is anticipated that modification or reduction of ice formation in cryopreserved valves should decrease the need for reoperation due to structural deterioration and calcification in allograft recipients.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R44
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    407864
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:407864\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ORGAN RECOVERY SYSTEMS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    CHARLESTON
  • Organization State
    SC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    294035000
  • Organization District
    UNITED STATES